Answers are grounded in this paper and cite their sources.
This case highlights the importance of vigilance for both thrombotic and inflammatory adverse events in patients with common variable immunodeficiency who are receiving intravenous immunoglobulin. It demonstrates that a multifaceted approach, including altering the product, infusion rate, and premedication, can effectively manage these complex complications.
No takes yet. Share an insight, caveat, or question.
Butz et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: